Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
June 07, 2023 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
June 05, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
- Plan to Initiate a Phase 1 Study of FHD-286 in Combination with Decitabine or Cytarabine in Relapsed and/or Refractory AML Patients in Q3’2023 - Clinical and Pre-Clinical Data Suggest FHD-286 Has...
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
May 08, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
Data from Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma expected in the second quarter of 2023 Selective BRM, ARID1B, EP300 and CBP, targeting key...
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
April 25, 2023 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Provides an Update on FHD-609
April 24, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting
April 10, 2023 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
April 06, 2023 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
March 09, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial safety and efficacy data expected in the first half of 2023 - Phase 1...
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
March 01, 2023 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
January 09, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1...